Product News
Filter News
Found 217,486 articles
-
In the meeting, both the FDA and the U.S. Centers for Disease Control and Prevention presented details about COVID-19 and the requirements for a vaccine.
-
Shaun Thaxter, the former chief executive officer of Indivior, was sentenced in federal court Thursday, four months after pleading guilty to one misdemeanor count of sharing false information about the addictive properties of Suboxone Film, an opioid-based product.
-
OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.
-
The pharmaceutical supply chain is being pushed to its limit as it prepares to deliver COVID-19 vaccines and therapeutics to the entire world as soon as possible, while continuing to produce and deliver all the usual medications and products.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
-
Two Phase III studies showed significant reduction in urinary oxalate excretion in patients of all ages with PH1.
-
Study Suggests Bayer’s Finerenone Slows CKD Progression in Patients With Kidney Disease and T2D
10/23/2020
The findings from this study were presented at the virtual American Society of Nephrology’s (ASN) Kidney Week 2020 on October 23, and the full study was published in a recent online edition of the New England Journal of Medicine. -
Arixa Pharmaceuticals announced on Thursday that Pfizer’s hospital business has agreed to acquire the company. Arixa has been developing oral antibiotics for antibiotic-resistant Gram-negative infections.
-
After discovering promising indicators on the path to the development of Branaplam (LMIO70) for spinal muscular atrophy, Novartis now hopes to repurpose the drug for the treatment of Hungtington’s disease.
-
Advanced Reimbursement Solutions, LLC., Holds Blue Cross Blue Shield Of Arizona Accountable For Benefits, Advocates For Patient After Insurance Bills Patient $25K
10/23/2020
Advanced Reimbursement Solutions LLC (ARS), a Scottsdale-based medical billing and revenue cycle management enterprise, challenged Blue Cross Blue Shield of Arizona (BCBS of AZ) for its approval and subsequent denial of a double-mastectomy patient.
-
IntelGenx Announces Second Tranche Closing of Private Placement
10/23/2020
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed a private placement (the “Offering”) to certain investors in the United States of U.S.$532,000 principal amount of 8% convertible notes due October 15, 2024 (the “Notes”).
-
Precision NanoSystems Receives $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19
10/23/2020
Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine.
-
/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./
10/23/2020
In the news release, BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate, issued Oct. 23, 2020 by BiondVax Pharmaceuticals Ltd. over PR Newswire, we are advised by the company that the Forward Looking Statements were not included. The complete, corrected release follows: BiondVax Announces Topline Results from P
-
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine Candidate
10/23/2020
Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines.
-
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
10/23/2020
Canadian government to provide $173M in funding for vaccine research and development, and domestic manufacturing capacity
-
PAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory Approval
10/23/2020
PAO Group, Inc. (USOTC: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).
-
Life Sciences Ontario Responds to Publication of Final PMPRB Guidelines
10/23/2020
LSO remains concerned by today’s release of the final PMPRB guidelines implementing the federal government’s patented medicine price controls. The final guidelines create a highly risky and uncertain pathway for commercializing new medicines and vaccines in Canada. LSO President and CEO Jason Field wants to ask the Government of Canada “why did it take four months for the PMPRB to publish guidelines that contain no sub
-
Global 7 Diagnostics Gets America Back to School and Work with Rapid COVID-19 Saliva Testing
10/23/2020
Global 7 Diagnostics, a leading clinical laboratory testing facility with an extensive molecular test menu, has been named one of a few select laboratories authorized to offer Yale University's revolutionary SalivaDirectTM test
-
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
10/23/2020
iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft ® Axxent ® Electronic Brachytherapy (eBx ® ) System ® at the American Society for Radiation Oncology ( ASTRO ) Virtual Annual Meeting, October 24-28, 2020. Researchers will present new data supporting the Xoft System for the treatment of early-s